Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

First Posted Date
2021-06-22
Last Posted Date
2024-02-20
Lead Sponsor
SUNHO（China）BioPharmaceutical CO., Ltd.
Target Recruit Count
97
Registration Number
NCT04934514
Locations
🇨🇳

The First Hospital of China Medical University, Shenyang, Liaoning, China

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

First Posted Date
2021-06-11
Last Posted Date
2024-11-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT04924101
Locations
🇺🇸

UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States

🇺🇸

MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States

🇺🇸

Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States

and more 46 locations

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

First Posted Date
2021-06-11
Last Posted Date
2024-03-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
158
Registration Number
NCT04924062
Locations
🇨🇳

Anhui Provincial Hospital ( Site 0140), Hefei, Anhui, China

🇨🇳

Beijing Cancer Hospital ( Site 0138), Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital ( Site 0150), Beijing, Beijing, China

and more 19 locations

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

First Posted Date
2021-06-10
Last Posted Date
2021-06-10
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
53
Registration Number
NCT04922450
Locations
🇨🇳

Hunan cancer Hospital, Changsha, Hunan, China

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

First Posted Date
2021-06-09
Last Posted Date
2023-11-03
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
15
Registration Number
NCT04920344
Locations
🇺🇸

RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick, New Jersey, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Rutgers Cancer Institute of New Jersey at University Hospital, Newark, New Jersey, United States

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

First Posted Date
2021-06-02
Last Posted Date
2021-06-02
Lead Sponsor
Ruijin Hospital
Target Recruit Count
40
Registration Number
NCT04909775
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers

First Posted Date
2021-05-19
Last Posted Date
2023-11-30
Lead Sponsor
Jennifer Choe
Registration Number
NCT04892875

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

First Posted Date
2021-05-18
Last Posted Date
2021-05-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
622
Registration Number
NCT04890522
Locations
🇨🇳

Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

First Posted Date
2021-05-14
Last Posted Date
2024-03-22
Lead Sponsor
G1 Therapeutics, Inc.
Target Recruit Count
92
Registration Number
NCT04887831
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Beacon Cancer Center PLLC, Coeur d'Alene, Idaho, United States

🇫🇷

Institut Bergonié - Oncologie Médicale et Pédiatrique, Bordeaux cedex, Gironde, France

and more 31 locations

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

First Posted Date
2021-05-13
Last Posted Date
2021-05-13
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT04884906
Locations
🇨🇳

TianjinCIH, Tianjin, Tianjin, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy